Top Page
Bioxyne Limited
(Sydney:BXN)
Bioxyne Limited (BXN) vs. iShares MSCI Australia ETF (EWA)
Bioxyne Limited Business Overview & Revenue Model
Bioxyne Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.42M | 30.42M | 9.33M | 5.16M | 463.64K | 2.11M |
| Gross Profit | 10.45M | 10.45M | 3.40M | 343.13K | -224.10K | 639.71K |
| EBITDA | 5.34M | 5.34M | -13.03M | -1.88M | -463.30K | -425.93K |
| Net Income | 4.90M | 4.90M | -13.33M | -1.94M | -494.02K | -495.73K |
Balance Sheet | ||||||
| Total Assets | 20.90M | 20.90M | 6.70M | 17.69M | 445.59K | 2.68M |
| Cash, Cash Equivalents and Short-Term Investments | 7.67M | 7.67M | 1.03M | 3.85M | 65.93K | 1.60M |
| Total Debt | 1.53M | 1.53M | 710.42K | 558.61K | 397.39K | 47.46K |
| Total Liabilities | 9.53M | 9.53M | 3.40M | 2.69M | 810.43K | 744.75K |
| Stockholders Equity | 11.68M | 11.68M | 3.61M | 15.14M | -364.84K | 1.88M |
Cash Flow | ||||||
| Free Cash Flow | 3.86M | 3.86M | -4.05M | -897.92K | -566.88K | 19.47K |
| Operating Cash Flow | 6.28M | 6.28M | -3.56M | -841.28K | -506.81K | 53.13K |
| Investing Cash Flow | -2.07M | -2.41M | -492.66K | 4.10M | 26.61K | -33.66K |
| Financing Cash Flow | 2.42M | 2.76M | 1.21M | 805.36K | 493.24K | -46.78K |
Bioxyne Limited Technical Analysis
Bioxyne Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$127.75M | 18.21 | 10.07% | 2.29% | 38.25% | 361.54% | |
71 Outperform | AU$92.21M | 17.50 | 61.21% | ― | 204.87% | ― | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | AU$38.08M | -1.58 | -31.14% | ― | -15.07% | 29.45% | |
43 Neutral | AU$33.11M | 39.13 | ― | ― | 6.76% | ― | |
41 Neutral | AU$6.55M | -2.02 | -60.84% | ― | -18.70% | 20.83% | |
38 Underperform | AU$7.00M | -0.20 | -184.71% | ― | 39.53% | 49.99% |
Bioxyne Limited Corporate Events
Bioxyne Limited has appointed Mr. Paul Mitchell as the Chief Financial Officer of its subsidiary, Breathe Life Sciences, to enhance its financial leadership amid rapid growth. Mr. Mitchell’s extensive experience in strategic planning and pharmaceutical manufacturing will support the company’s expansion in manufacturing and distributing controlled medicines, including medicinal cannabis, psilocybin, and MDMA, across Australia and the UK, aligning with Bioxyne’s ambitious international strategy.
Bioxyne Limited announced that all resolutions were successfully passed during its Annual General Meeting held on November 26, 2025. The resolutions included the re-election of directors, approval of performance rights, and ratification of placement shares and options, indicating strong shareholder support and potential for strategic growth initiatives.
Bioxyne Limited announced significant growth and strategic advancements at its 2025 Annual General Meeting. The company reported record sales and profits for FY2025, driven by its expansion in manufacturing capacity and international markets, particularly in Europe. Bioxyne’s release of Australian-made GMP MDMA capsules for clinical trials marks a milestone in mental health treatment, positioning the company at the forefront of the psychedelic therapeutics market. The company also secured major contracts and invested in infrastructure to support its growth, achieving a 210% increase in quarterly revenue in Q1 FY2026.
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has dispatched its second shipment of Australian-manufactured GMP MDMA capsules to support a clinical trial by the Victorian Government’s Eastern Health. This trial investigates MDMA-assisted psychotherapy for patients with co-occurring PTSD and borderline personality disorder, highlighting the growing demand and Bioxyne’s positioning as Australia’s first domestic supplier of pharmaceutical-grade MDMA and psilocybin. The initiative is part of a broader trend towards psychedelic-assisted therapies, which are gaining acceptance globally, and is expected to drive significant growth alongside Bioxyne’s core medicinal cannabis and consumer health businesses.
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has announced the release of GMP manufactured MDMA capsules for clinical trials in Victoria and authorized prescriber dispensing in Queensland. This strategic move positions Bioxyne at the forefront of innovative mental health treatments in Australia, addressing the significant need for effective PTSD therapies and leveraging the growing global psychedelic drugs market.
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured an exclusive agreement with Curaleaf International to import, manufacture, and distribute the Que Medical Inhalation Device in Australia. This device, designed for medical cannabis liquid inhalants, is set to launch in November 2025, marking a significant expansion in Bioxyne’s operations and strengthening its position in the medical device sector. The partnership is expected to generate a strong revenue stream, supporting Bioxyne’s financial targets and enhancing access to regulated inhalation technology in Australia.
Bioxyne Limited has released its first quarter results for FY2025, highlighting its continued focus on innovative health and wellness products. The company’s subsidiary, Breathe Life Sciences, has expanded its operations internationally, solidifying its position as a leader in the manufacturing and distribution of therapeutic goods, including cannabis-based products. This expansion is expected to enhance Bioxyne’s market presence and offer significant growth opportunities in the pharmaceutical and consumer health sectors.
Bioxyne Limited reported a record quarterly revenue of $14.1 million, marking a 210% increase from the previous year and a 47% rise from the last quarter. This growth is attributed to substantial investments in cannabis flower procurement to meet European demand, with significant contributions from Breathe Life Sciences Australia. The company completed a dual listing on the Frankfurt Stock Exchange and is expanding its operations in Europe and the UK, supported by positive regulatory developments in Germany and the United States.
Bioxyne Limited has announced its upcoming Annual General Meeting scheduled for November 26, 2025, in Sydney. Shareholders are encouraged to lodge proxy forms and submit questions in advance. This meeting is significant for stakeholders as it reflects the company’s commitment to transparency and shareholder engagement, potentially impacting its strategic direction and market positioning.
Bioxyne Limited has announced its Annual General Meeting (AGM) scheduled for Wednesday, 26 November 2025, at Addisons in Sydney. Shareholders are encouraged to participate in the meeting, where they will have the opportunity to ask questions and vote on resolutions via a poll. The company has provided a Proxy Form for shareholders to record their votes in advance, emphasizing the importance of shareholder engagement in the decision-making process.
Bioxyne Limited has announced a change in the director’s interest notice, specifically relating to Mr. Jason Hine. The change involves the acquisition of 4,500,000 performance rights, awarded due to the achievement of performance milestones for 2023 to 2025. This adjustment in securities reflects the company’s ongoing commitment to aligning director incentives with performance targets, potentially impacting the company’s governance and stakeholder confidence.
Bioxyne Limited has announced the quotation of 18 million ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 27, 2025. This move, part of an employee incentive scheme, is expected to enhance the company’s market presence and potentially increase shareholder value by expanding its capital base.
Bioxyne Limited has announced its dual listing on the Frankfurt Stock Exchange, aiming to engage with global investors and enhance its presence in the European market. This strategic move aligns with the company’s focus on Europe, supported by a recent supply agreement and the appointment of a European Investor Relations Specialist. The dual listing is expected to increase Bioxyne’s visibility and provide greater access to European investors, particularly in Germany, where the legal cannabis market is expanding rapidly.
Recent developments in U.S. cannabis classification, specifically the potential rescheduling of cannabis to a Schedule III substance, could significantly impact the regulatory environment and investment climate for cannabinoid and psychedelic-derived therapeutics. This change may facilitate broader research access, ease banking and tax constraints, and attract institutional investment, creating momentum in the cannabis sector. Bioxyne Limited is well-positioned to benefit from these changes, potentially accelerating its growth strategy through improved capital access and reduced regulatory friction, even though the changes do not directly affect Australian regulations.
Bioxyne Limited has updated its corporate governance statement, which is now available on its website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, highlighting its commitment to transparency and accountability. This update reinforces Bioxyne’s dedication to maintaining high governance standards, potentially strengthening its position in the industry and reassuring stakeholders of its operational integrity.
Bioxyne Limited has received import authorizations from the German Government for 1,550kg of medical cannabis products, marking its entry into the German cannabis market. The company has secured purchase orders worth A$5.1 million, with exports planned for late September or early October. This development is expected to enhance Bioxyne’s market positioning in Europe, with future orders potentially exceeding the initial A$5.6 million contract, indicating a strong demand and positive outlook for the company’s operations and stakeholders.